<DOC>
	<DOCNO>NCT00003103</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness oblimersen treat patient solid tumor respond previous therapy .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety plasma concentration profile oblimersen ( G3139 ) administer alone combination docetaxel patient advance solid tumor express bcl-2 oncogene . II . Determine plasma concentration profile , maximum tolerate dose ( MTD ) , and/or optimal biologic dose ( OBD ) treatment regimen patient . III . Determine antitumor effect G3139 , MTD OBD , combination docetaxel patient androgen-independent , refractory , recurrent prostate cancer . OUTLINE : This dose-escalation study oblimersen ( G3139 ) . Phase I : Patients receive G3139 IV day 1-5 docetaxel IV day 5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos G3139 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose-limiting toxicity . Phase II : Patients receive G3139 continuously 21 day one dose level MTD combination weekly docetaxel . Patients receive 2 course therapy absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression . PROJECTED ACCRUAL : A maximum 57 patient ( 42 phase I 15 phase II ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I : Histologically proven advanced , primary , malignant solid tumor refractory standard therapy curative therapy exist Androgenindependent prostate cancer Head neck cancer Breast cancer Nonsmall cell lung cancer Colorectal cancer Ovarian cancer Esophageal cancer Bladder cancer Kidney cancer Other solid tumor Metastatic disease require palliative treatment within 4 week enrollment Phase II : Histologically proven androgenindependent prostate cancer Serum testosterone less 30 ng/mL Failed least one prior chemotherapy regimen Progressive Minimum 3 rise PSA value baseline obtain least 1 week apart OR Two rise PSA value one month apart AND At least 25 % increase range value AND PSA least 4 ng/mL No active CNS epidural tumor Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Not specify Menopausal status : Not specify Performance status : Karnofsky 60100 % Life expectancy : At least 6 month Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL SGOT le 3 time upper limit normal Prothrombin time le 14 second Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV cardiac disease Pulmonary : No severe debilitate pulmonary disease Other : Not pregnant nursing Fertile patient must use effective contraception No active infection No severe medical problem PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy recover Endocrine therapy : Concurrent medical therapy ( i.e. , gonadotropin release hormone analog diethylstilbestrol ) maintain castrate level serum testosterone allow No concurrent hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy recover Concurrent radiotherapy localize site disease evaluate study allow Surgery : Not specify Other : At least 4 week since prior investigational anticancer therapy recover No concurrent intravenous antibiotic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III Wilms tumor</keyword>
	<keyword>stage IV Wilms tumor</keyword>
	<keyword>stage V Wilms tumor</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
	<keyword>rhabdoid tumor kidney</keyword>
</DOC>